Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States

Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United States in 2006 and through 2015 was the predominate HPV vaccine used. With the exception of syncope, a known preventable adverse event after any injected vaccination, both pre-licensure and post-licensure 4vHPV safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gee, Julianne, Weinbaum, Cindy, Sukumaran, Lakshmi, Markowitz, Lauri E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964727/
https://www.ncbi.nlm.nih.gov/pubmed/27029786
http://dx.doi.org/10.1080/21645515.2016.1168952
_version_ 1782445160511045632
author Gee, Julianne
Weinbaum, Cindy
Sukumaran, Lakshmi
Markowitz, Lauri E.
author_facet Gee, Julianne
Weinbaum, Cindy
Sukumaran, Lakshmi
Markowitz, Lauri E.
author_sort Gee, Julianne
collection PubMed
description Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United States in 2006 and through 2015 was the predominate HPV vaccine used. With the exception of syncope, a known preventable adverse event after any injected vaccination, both pre-licensure and post-licensure 4vHPV safety data have been reassuring with no confirmed safety signals identified. Nine-valent HPV vaccine (9vHPV) was licensed in 2014. This review includes post-licensure 4vHPV safety findings published to date that have informed the US vaccination program; these data will inform US safety monitoring and evaluation for 9vHPV.
format Online
Article
Text
id pubmed-4964727
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49647272016-11-29 Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States Gee, Julianne Weinbaum, Cindy Sukumaran, Lakshmi Markowitz, Lauri E. Hum Vaccin Immunother Reviews Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United States in 2006 and through 2015 was the predominate HPV vaccine used. With the exception of syncope, a known preventable adverse event after any injected vaccination, both pre-licensure and post-licensure 4vHPV safety data have been reassuring with no confirmed safety signals identified. Nine-valent HPV vaccine (9vHPV) was licensed in 2014. This review includes post-licensure 4vHPV safety findings published to date that have informed the US vaccination program; these data will inform US safety monitoring and evaluation for 9vHPV. Taylor & Francis 2016-03-30 /pmc/articles/PMC4964727/ /pubmed/27029786 http://dx.doi.org/10.1080/21645515.2016.1168952 Text en © 2016 The Author(s). This article not subject to US copyright law http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Reviews
Gee, Julianne
Weinbaum, Cindy
Sukumaran, Lakshmi
Markowitz, Lauri E.
Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
title Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
title_full Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
title_fullStr Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
title_full_unstemmed Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
title_short Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
title_sort quadrivalent hpv vaccine safety review and safety monitoring plans for nine-valent hpv vaccine in the united states
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964727/
https://www.ncbi.nlm.nih.gov/pubmed/27029786
http://dx.doi.org/10.1080/21645515.2016.1168952
work_keys_str_mv AT geejulianne quadrivalenthpvvaccinesafetyreviewandsafetymonitoringplansforninevalenthpvvaccineintheunitedstates
AT weinbaumcindy quadrivalenthpvvaccinesafetyreviewandsafetymonitoringplansforninevalenthpvvaccineintheunitedstates
AT sukumaranlakshmi quadrivalenthpvvaccinesafetyreviewandsafetymonitoringplansforninevalenthpvvaccineintheunitedstates
AT markowitzlaurie quadrivalenthpvvaccinesafetyreviewandsafetymonitoringplansforninevalenthpvvaccineintheunitedstates

Ejemplares similares